Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
Pyxis Oncology, Inc. (PYXS)
Company Research
Source: GlobeNewswire
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. “We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. “Santhosh’s guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical development of our lead asset, PYX-201, a first-in-class and first-in-concept tumor stroma targeting ADC against EDB-fibronectin. His background is highly complementary with those of our other Board members, and I look forward to beginning our work together to drive Pyxis Oncology’s future growth.” Dr.
Show less
Read more
Impact Snapshot
Event Time:
PYXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PYXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PYXS alerts
High impacting Pyxis Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
PYXS
News
- Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect? [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology, Inc. (NASDAQ: PYXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait [Seeking Alpha]Seeking Alpha
PYXS
Earnings
- 11/7/23 - Beat
PYXS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/26/24 - Form DEFA14A
- PYXS's page on the SEC website